NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

29641.10 533.05 (1.83%)

5,764 NSE+BSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

62,985.3

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Abbott India Ltd.

11 Feb 2022, 12:00AM

29641.10

1.83%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott's top 10 brands - (Mixtard, Thyronorm, Novomix, Udiliv, Duphaston) together posted revenue CAGR of ~7% MAT, December 2018-22 Abbott has 140+ brands in segments of women's health, gastroenterology,...

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

10 Feb 2022

29641.10

1.83%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

The company is expected to report Revenue/PAT CAGR of 11.1% and 11.3% 0ver FY21-FY24E backed by stable sales in the Duphaston brand, an increase in volume in the Thyronorm brand, and a pick-up in the IPM growth. Therefore, we recommend a BUY rating on the stock with a Target Price of Rs 20,000/share

Abbott India Ltd. has an average target of 31900.00 from 3 brokers.

Abbott India Ltd.

10 Jan 2022

29641.10

1.83%

Pick of the Week:10 JAN 2022

Buy: Abbott India Ltd.

Target

Axis Direct

We recommend BUY with a TP of Rs 20,000/share.

Abbott India Ltd. is trading below its 30 day SMA of 30258.0

Abbott India Ltd.

15 Nov 2021

29641.10

1.83%

Result Update:Abbott India

Buy: Abbott India Ltd.

Recommendation Target

Axis Direct

We recommend a BUY rating on the stock with a Target Price of Rs 22,400/share.

Abbott India Ltd. is trading below its 30 day SMA of 30258.0

Abbott India Ltd.

22 Sep 2021

29641.10

1.83%

Axis Annual Analysis:Abbott India

Hold: Abbott India Ltd.

Target

Axis Direct

We expect Revenue/PAT CAGR of 11.1%/11.3% respectively over FY21-FY24E. While a TP of Rs 20,000 implies a marginal downside of 2.5%, we remain positive on the long-term outlook of the company and recommend a HOLD rating on the stock.

Abbott India Ltd.'s price crossed above 50Day SMA today

Abbott India Ltd.

09 Aug 2021

29641.10

1.83%

Result Update:Abbott India

Hold: Abbott India Ltd.

Target

Axis Direct

We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3% respectively 0ver FY21-FY24E. However, considering rich valuations (PE 40x for FY24E), we recommend HOLD with a target price of Rs 18,000/share.

Abbott India Ltd. is trading below its 30 day SMA of 30258.0

Abbott India Ltd.

07 Aug 2021

29641.10

1.83%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

The company's top five brands - (Duphaston gynaecological, Thyronorm thyroid, Udiliv, Duphalac both GI and Vertin- CNS) together posted revenue CAGR of ~13% in March 2017-21 (MAT basis) Abbott has 140+ brands in segments of women's health, gastroenterology,...

Abbott India Ltd. is trading below its 30 day SMA of 30258.0

Abbott India Ltd.

19 May 2021

29641.10

1.83%

Result Update:Abbott India

Hold: Abbott India Ltd.

Target

Axis Direct

It is expected that competition to the Duphaston brand and stable volume in Thyronorm could result in lower revenue in upcoming quarters for Abbott India. We, therefore, recommend HOLD' on the stock with a target price of Rs 15,800/share.

Abbott India Ltd. is trading below its 30 day SMA of 30258.0

Abbott India Ltd.

19 May 2021

29641.10

1.83%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Covid-19 related disturbances notwithstanding, companies from the pharma MNC staple like Abbott continue to generate investor's interest with robust and sustainable business model backed by stable growth, debt-free b/s, favourable market dynamics with doctor prescription stickiness and lower perceived risk factors. We continue to believe in Abbott's strong growth track in power brands and capability in new launches on a fairly consistent basis (+100 launches in the last 10 years). We maintain BUY and arrive at a target price of | 19235 (vs. earlier | 19065)...